Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1997 1
2007 1
2010 2
2011 1
2013 1
2017 1
2018 2
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Miller TM, et al. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. N Engl J Med. 2022. PMID: 36129998 Free article. Clinical Trial.
A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis.
Clawson LL, Cudkowicz M, Krivickas L, Brooks BR, Sanjak M, Allred P, Atassi N, Swartz A, Steinhorn G, Uchil A, Riley KM, Yu H, Schoenfeld DA, Maragakis NJ; neals consortium. Clawson LL, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):250-258. doi: 10.1080/21678421.2017.1404108. Epub 2017 Nov 30. Amyotroph Lateral Scler Frontotemporal Degener. 2018. PMID: 29191052 Clinical Trial.
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis.
Quintana M, Saville BR, Vestrucci M, Detry MA, Chibnik L, Shefner J, Berry JD, Chase M, Andrews J, Sherman AV, Yu H, Drake K, Cudkowicz M, Paganoni S, Macklin EA; HEALEY ALS Platform Trial Study Group. Quintana M, et al. Ann Neurol. 2023 Sep;94(3):547-560. doi: 10.1002/ana.26714. Epub 2023 Jun 22. Ann Neurol. 2023. PMID: 37245090
Stable Decoding from a Speech BCI Enables Control for an Individual with ALS without Recalibration for 3 Months.
Luo S, Angrick M, Coogan C, Candrea DN, Wyse-Sookoo K, Shah S, Rabbani Q, Milsap GW, Weiss AR, Anderson WS, Tippett DC, Maragakis NJ, Clawson LL, Vansteensel MJ, Wester BA, Tenore FV, Hermansky H, Fifer MS, Ramsey NF, Crone NE. Luo S, et al. Among authors: clawson ll. Adv Sci (Weinh). 2023 Dec;10(35):e2304853. doi: 10.1002/advs.202304853. Epub 2023 Oct 24. Adv Sci (Weinh). 2023. PMID: 37875404 Free PMC article.
Amyotrophic lateral sclerosis-specific quality of life-short form (ALSSQOL-SF): A brief, reliable, and valid version of the ALSSQOL-R.
Felgoise SH, Feinberg R, Stephens HE, Barkhaus P, Boylan K, Caress J, Clawson LL, Elman L, Goutman SA, Mccluskey L, Russell J, Tiryaki E, Weiss M, Simmons Z. Felgoise SH, et al. Among authors: clawson ll. Muscle Nerve. 2018 Nov;58(5):646-654. doi: 10.1002/mus.26203. Epub 2018 Oct 19. Muscle Nerve. 2018. PMID: 30028537 Free article.
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.
Lewis RA, McDermott MP, Herrmann DN, Hoke A, Clawson LL, Siskind C, Feely SM, Miller LJ, Barohn RJ, Smith P, Luebbe E, Wu X, Shy ME; Muscle Study Group. Lewis RA, et al. Among authors: clawson ll. JAMA Neurol. 2013 Aug;70(8):981-7. doi: 10.1001/jamaneurol.2013.3178. JAMA Neurol. 2013. PMID: 23797954 Free PMC article. Clinical Trial.
12 results